期刊文献+

2003—2007年我院1073株铜绿假单胞菌的临床分布及耐药性监测 被引量:12

Clinical distribution and antibiotics resistance surveillance of 1 073 strains of pseudomonas aeruginosa in People's Hospital of Xinjiang Autonomous Region,2003—2007
暂未订购
导出
摘要 目的分析2003—2007年我院1073株铜绿假单胞菌对抗菌药物的耐药情况。方法采用全自动微生物分析仪VITEK32进行细菌鉴定,用GNS药敏卡及Kirty-Bauer法进行药敏试验。结果5年来,1073株铜绿假单胞菌以下呼吸道标本中最为常见(61.4%)。以ICU、呼吸科ICU、外科ICU检出率最高(57.8%)对16种抗菌药物耐药率较低的有头孢哌酮-舒巴坦(17.0%)、美罗培南(18.5%)、阿米卡星(19.6%)、亚胺培南(24.2%)、头孢吡肟(25.7%)、哌拉西林-他唑巴坦(35.7%)和头孢他啶(36.7%)。虽然头孢哌酮-舒巴坦、头孢他啶的耐药率较低但中介率较高,分别达15.2%、12.5%,应引起临床医师高度重视。结论连续5年回顾性分析,铜绿假单胞菌是我院医院感染的主要病原菌,对16种抗菌药物的耐药性相当严重,且常呈多重耐药,给临床抗感染治疗带来很大的困难。应重视耐药菌株监测,对临床合理用药有指导作用和实用价值。 Objective To analyze the pattern of antibiotic resistance in 1 073 strains of Pseudomonas aeruginosa in People's Hospital of Xinjiang Autonomous Region during 2003-2007. Methods Automated microbe analyzer (VITEK32) was used to analyze antibiotic susceptibility by means of GNS drug sensitivity card and Kirty-Bauer method. Results In recent five years, 1 073 strains of P. aeruginosa were isolated from respiratory specimens, most of which were from ICU, respiratory ICU and surgery ICU (57.8 %). Among the 16 antibiotics tested, these strains showed the lowest resistance (17.0%) to cefoperazonesulbactam, followed by meropenem (18.5%), amikacin (19. 6%), imipenem (24. 2%), cefepime (25. 7%), piperacillintazobaetam (35.7%) and ceftazidime (36.7%). Although the resistance to cefoperazone-sulbactam and ceftazidime was relatively lower, the prevalence of intermediate strains was relatively higher, 15.2% and 12.5% respectively. Conclusions The antibiotic resistance surveillance results of five consecutive years indicate that P. aeruginosa was one of the most common pathogens in this hospital associated with serious issue of antibiotic resistance.
作者 李娟 李智伟
出处 《中国感染与化疗杂志》 CAS 2009年第4期286-288,共3页 Chinese Journal of Infection and Chemotherapy
关键词 铜绿假单胞菌 耐药性 感染 Pseudomonas aeruginosa drug resistance infection
  • 相关文献

参考文献9

  • 1倪语星,乔静贤,项明洁,张轶,毛向群.上海瑞金医院1887株临床分离菌的耐药性分析[J].中华医学检验杂志,1998,21(2):102-103. 被引量:118
  • 2李爱娟.309株假单胞菌的分离鉴定及药敏试验[J].中华医院感染学杂志,2003,13(5):479-480. 被引量:6
  • 3陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 4于宗河 徐秀华.临床医院感染学[M].长沙:湖南科技技术出版社,1998.8-9.
  • 5Akasaka T,Tanaka M, Yamaguchi A, et al. Type Ⅱ topoimutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999 :role of target enzyme in mechanism of fluoroquinolone resistance[J ]. Antimicrob Agents Chemother, 2001,45 (8) 2263-2268.
  • 6Mouneimne H, Robert J, Jarlier V, et al. Type Ⅱ topoisomerase mutations in ciprofloxacin-resistance strains of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999,43 ( 1 ) : 6262-6266.
  • 7Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype in a new family of transporters [J]. Mol Microbiol,1999,31(1) :394-395.
  • 8Troiller N,Samore MH, Carmeli T, et al. Imipenem-resistant Pseudomonas aeruginosa : risk factors and antibiotic susceptibility patterns [J ]. Clin Infect Dis, 1997, 25 ( 5 ) : 1094 1098.
  • 9李家泰,李耘,齐慧敏,代表中国细菌耐药监测研究组.2002—2003年中国革兰阴性细菌耐药性监测研究[J].中华检验医学杂志,2005,28(1):19-29. 被引量:296

二级参考文献24

  • 1National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
  • 2Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
  • 3Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
  • 4Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
  • 5Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
  • 6Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 7Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 8Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 9Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 10National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.

共引文献912

同被引文献78

引证文献12

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部